EVGN Stock Overview
Evogene Ltd., together with its subsidiaries, operates as a computational biology company.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Evogene Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.74 |
| 52 Week High | ₪1.44 |
| 52 Week Low | ₪0.45 |
| Beta | 1.16 |
| 1 Month Change | -9.40% |
| 3 Month Change | -14.61% |
| 1 Year Change | 28.07% |
| 3 Year Change | -81.88% |
| 5 Year Change | -65.76% |
| Change since IPO | -44.97% |
Recent News & Updates
Recent updates
Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots
Oct 12Evogene unit launches 2nd-gen medical cannabis products in Israel
Sep 21Lavie Bio appoints Guri Oron as CEO
Sep 14Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M
Aug 31Evogene regains compliance with Nasdaq's minimum bid price requirement
Aug 25Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement
Aug 17Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Mar 22Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)
Mar 03Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market
Sep 14Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets
Jun 16Evogene EPS beats by $0.01, beats on revenue
May 26Evogene unit - Canonic inks cultivation deal for medical cannabis varieties
Dec 23AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program
Dec 15Evogene: Q3 Update And Upcoming Catalysts
Nov 30Shareholder Returns
| EVGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.9% | -2.8% | -1.7% |
| 1Y | 28.1% | -0.2% | 22.4% |
Return vs Industry: EVGN exceeded the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: EVGN exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| EVGN volatility | |
|---|---|
| EVGN Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EVGN's share price has been volatile over the past 3 months.
Volatility Over Time: EVGN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 142 | Ofer Haviv | www.evogene.com |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Evogene Ltd. Fundamentals Summary
| EVGN fundamental statistics | |
|---|---|
| Market cap | US$37.45m |
| Earnings (TTM) | -US$23.88m |
| Revenue (TTM) | US$5.64m |
6.6x
P/S Ratio-1.6x
P/E RatioIs EVGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVGN income statement (TTM) | |
|---|---|
| Revenue | US$5.64m |
| Cost of Revenue | US$1.69m |
| Gross Profit | US$3.95m |
| Other Expenses | US$27.83m |
| Earnings | -US$23.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 70.00% |
| Net Profit Margin | -423.39% |
| Debt/Equity Ratio | 0% |
How did EVGN perform over the long term?
See historical performance and comparison